Competitor Analysis: GLP-1 Receptor Agonists

  • ID: 661456
  • Report
  • Region: Global
  • 71 Pages
  • La Merie Publishing
1 of 4

FEATURED COMPANIES

  • Addex Pharmaceuticals
  • Bio-ker
  • Emisphere Technologies
  • Ipse
  • OctoPlus
  • Roche (& Chugai)
  • MORE
The Competitive Intelligence Report Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists as of August 2014 provides a competitor analysis in the development pipeline of novel GLP-1 analogs and GLP-1 receptor agonists and co-agonists for treatment of diabetes and obesity.

In the year 2013, the marketed daily and weekly GLP-1 agonists achieved combined sales of US$ 3,231 mln representing 6.3% of the total diabetes care market. The leading GLP-1 analog Victoza held 69% of the GLP-1 market and is further expanding its predominance in the first half of 2014 with a 72% share of the GLP-1 market which grew to 6.9% of the total diabetes care market.

The increasingly attractive GLP-1 market provides an opportunity of application of new technologies to prolong the half-life of GLP-1 analogs as well as finding co-agonists of GLP-1 receptor with additional receptors, such as insulin, glucagon, GIP, gastrin or GLP-1. In addition, expansion of indications for GLP-1 analogs will contribute to further expand the GLP-1 market.

The report provides a compilation of current active projects in research and development of novel GLP-1 analogs and GLP-1 receptor agonists as well as co-agonists. Competitor projects are listed in a tabular format providing information on:

- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Addex Pharmaceuticals
  • Bio-ker
  • Emisphere Technologies
  • Ipse
  • OctoPlus
  • Roche (& Chugai)
  • MORE
1. Selective GLP-1 Analogs for Metabolic Diseases

2013 Sales of GLP-1 Analogs
Short-Acting Injectable GLP-1 Analogs
Long-Acting Injectable GLP-1 Analogs
Very Long-Acting Injectable GLP-1 Analogs
Oral Peptide-Based GLP-1 Analogs
Other Non-Injectable Peptide-Based GLP-1 Analogs
Oral Small Molecule GLP-1 Receptor Agonists

2. Selective GLP-1 Analogs for Non-Metabolic Diseases

3. Dual Target GLP-1 Analogs

GLP-1 and Insulin
GLP-1 and Glucagon
GLP-1 and GIP
GLP-1 and Gastrin/CCKB
GLP-1 and GLP-2

4. Corporate GLP-1 Receptor Agonist R&D Pipelines
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
- Addex Pharmaceuticals
- Amylin Pharmaceuticals
- Arisaph Pharmaceuticals
- Arisgen
- Ascendis Pharma (Complex Biosystems)
- Bio-ker
- Biocompatibles International
- ConjuChem
- Dong-A Pharmaceutical
- Eli Lilly
- Emisphere Technologies
- Faust Pharmaceuticals
- GlaxoSmithKline
- Hanmi Pharmaceuticals
- Ipse
- Mannkind
- MDRNA (ex Nastech Pharmaceuticals)
- Modigene
- Novo Nordisk
- OctoPlus
- Oramed Pharmaceuticals
- Pfizer
- Proxima Concepts
- Roche (& Chugai)
- Rose Pharmaceuticals (ex Gastrotech)
- Sanofi-Aventis
- Teijin
- Transition Therapeutics
- TransTech Pharma
- Unigene
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll